Effects of Oxazepam, valerian, lavender and placebo on anxiety and sleep quality in patients with coronary artery disease

Comparison of effects of Oxazepam, Valeriana officinalis, Lavandula angustifolia Mill and placebo on anxiety and sleep quality in patients with coronary artery disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091429822N1

Enrollment

120

Registered

2016-12-31

Start date

2016-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease. Coronary Artery Disease

Interventions

Intervention 1: Lavender intervention group: 5 cc essential oil, every night for 3 nights. Intervention 2: Valerin intervention group: 5 cc extract of valerian, every night for 3 nights. Intervention

Treatment - Drugs

Placebo

Lavender intervention group: 5 cc essential oil, every night for 3 nights

Valerin intervention group: 5 cc extract of valerian, every night for 3 nights

Placebo group: 5 cc water, every night for 3 nights

Oxazepam intervention group: one 10 mg oxazepam dissolved in 5 ml of distilled water, every night for 3 nights

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 30 to 70 years; willingness to participate in the study; no risk of heart failure (class III and IV) and cardiogenic shock; no use of complementary alternative medicine methods (herbal medicines and other methods) during the two weeks preceding intervention; no use of sleeping drugs, benzodiazepines, and sedative drugs; no addiction; no history of allergy to flowers, plants, valerian and lavender; no history of mental illness; stable vital signs; gaining a score of above 20 on the Spielberger's State and Trait Anxiety Inventory; obtaining a score equal to or over 5 on the Pittsburgh's Sleep Quality Index. Exclusion criteria: No cooperation during the study; sudden changes in the patient's hemodynamic status

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sleep quality. Timepoint: before intervention and 3 days after intervention. Method of measurement: Pittsburgh Sleep Quality Index.;State and trait anxiety. Timepoint: before intervention and 3 days after intervention. Method of measurement: Spielberger's State and Trait Anxiety Inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Rafie Bigan

Birjand University of Medical Sciences

m.rafiee@bums.ac.ir; m_rafiee_201170@yahoo.com+98 56 3239 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026